Given their antitumor effects, somatostatin analogs such as octreotide and lanreotide (both are potent SSTR2 agonists but notably spare SSTR1) have been approved to treat gastroenteropancreatic NE tumors and carcinoid syndrome (57, 58). This evidence concerns the gene SSTR1 and carcinoid syndrome.